19/12/2008
GB00B39J5N63
Scancell Holdings Plc
('Scancell' or the 'Company')
Issue of Equity
The Directors of Scancell are pleased to announce that on 19 December 2008, the Company issued
73,333 new ordinary shares of 1p each in lieu of advisory fees relating to the admission of the
Company onto the PLUS-quoted market at a price of 60 pence per share.
The trading of the new ordinary shares on PLUS is expected to commence on 22 December 2008.
Following the issue of shares as detailed above the total number of ordinary shares in issue as at
19 December 2008 will be 10,275,551 ordinary shares. The total Directors' Shareholding as a result
of the Issue of Equity is 2,627,892 ordinary shares representing 25.57% of the current issued
share capital.
The Directors of the issuer accept responsibility for this announcement.
-ENDS-
For Further Information:
Professor Lindy Durrant Scancell Holdings Plc + 44 207 245 1100
Adam Reynolds/Vikki Krause Hansard Group + 44 7515 922906
Duncan Vasey/Barry Hocken St. Helen's Capital Plc + 44 207 628 5582
Scancell Holdings plc
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.